DexCom is a medical device company focusing on glucose monitoring systems mainly for diabetes patient with two main product lines: Ambulatory product line including SEVEN PLUS and G4 PLANTINUM and In-Hospital product line including GlucoClear. DexCom, Inc. (NASDAQ: DXCM ) has around 71 direct sales personnel to call on physicians and diabetes educators who could influence patient adoption of continuous glucose monitoring. The majority of its sales, $93 million, or nearly 93% of the total 2012 revenue, was generated from the product revenue while the development grant and other revenue contributed only $6.9 million in 2012 sales.